200 related articles for article (PubMed ID: 19015589)
1. Long-term treatment with valsartan improved cyclic variation of the myocardial integral backscatter signal and diastolic dysfunction in hypertensive patients: the echocardiographic assessment.
Mizuta Y; Kai H; Mizoguchi M; Osada K; Tahara N; Nakaura H; Kuwahara F; Imaizumi T;
Hypertens Res; 2008 Oct; 31(10):1835-42. PubMed ID: 19015589
[TBL] [Abstract][Full Text] [Related]
2. The effect of valsartan on left ventricular myocardial functions in hypertensive patients with left ventricular hypertrophy.
Kucukler N; Kurt IH; Topaloglu C; Gurbuz S; Yalcin F
J Cardiovasc Med (Hagerstown); 2012 Mar; 13(3):181-6. PubMed ID: 22306782
[TBL] [Abstract][Full Text] [Related]
3. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
Solomon SD; Skali H; Anavekar NS; Bourgoun M; Barvik S; Ghali JK; Warnica JW; Khrakovskaya M; Arnold JM; Schwartz Y; Velazquez EJ; Califf RM; McMurray JV; Pfeffer MA
Circulation; 2005 Jun; 111(25):3411-9. PubMed ID: 15967846
[TBL] [Abstract][Full Text] [Related]
4. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.
Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; O'Moore-Sullivan T; Marwick TH
JACC Cardiovasc Imaging; 2011 Dec; 4(12):1239-49. PubMed ID: 22172779
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy.
Yasunari K; Maeda K; Watanabe T; Nakamura M; Yoshikawa J; Asada A
J Am Coll Cardiol; 2004 Jun; 43(11):2116-23. PubMed ID: 15172423
[TBL] [Abstract][Full Text] [Related]
6. Clinical aspects of left ventricular diastolic function assessed by Doppler echocardiography following acute myocardial infarction.
Poulsen SH
Dan Med Bull; 2001 Nov; 48(4):199-210. PubMed ID: 11767125
[TBL] [Abstract][Full Text] [Related]
7. Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension.
Anan F; Takahashi N; Ooie T; Yufu K; Hara M; Nakagawa M; Yonemochi H; Saikawa T; Yoshimatsu H
Eur J Clin Pharmacol; 2005 Jul; 61(5-6):353-9. PubMed ID: 15918057
[TBL] [Abstract][Full Text] [Related]
8. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
[TBL] [Abstract][Full Text] [Related]
9. Effects of thrice-weekly in-center nocturnal vs. conventional hemodialysis on integrated backscatter of myocardial tissue.
Jin X; Rong S; Mei C; Ye C; Chen J; Chen X
Hemodial Int; 2011 Apr; 15(2):200-10. PubMed ID: 21395972
[TBL] [Abstract][Full Text] [Related]
10. Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure.
Kasama S; Toyama T; Kumakura H; Takayama Y; Ichikawa S; Suzuki T; Kurabayashi M
J Nucl Med; 2003 Jun; 44(6):884-90. PubMed ID: 12791814
[TBL] [Abstract][Full Text] [Related]
11. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial.
Solomon SD; Janardhanan R; Verma A; Bourgoun M; Daley WL; Purkayastha D; Lacourcière Y; Hippler SE; Fields H; Naqvi TZ; Mulvagh SL; Arnold JM; Thomas JD; Zile MR; Aurigemma GP;
Lancet; 2007 Jun; 369(9579):2079-87. PubMed ID: 17586303
[TBL] [Abstract][Full Text] [Related]
12. Acute administration of a single dose of valsartan improves left ventricular functions: a pilot study to assess the role of tissue velocity echocardiography in patients with systemic arterial hypertension in the TVE-valsartan study I.
Govind SC; Brodin LA; Nowak J; Ramesh SS; Saha SK
Clin Physiol Funct Imaging; 2006 Nov; 26(6):351-6. PubMed ID: 17042901
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study.
Verma A; Meris A; Skali H; Ghali JK; Arnold JM; Bourgoun M; Velazquez EJ; McMurray JJ; Kober L; Pfeffer MA; Califf RM; Solomon SD
JACC Cardiovasc Imaging; 2008 Sep; 1(5):582-91. PubMed ID: 19356485
[TBL] [Abstract][Full Text] [Related]
14. Hemodialysis improves myocardial interstitial edema and left ventricular diastolic function in patients with end-stage renal disease: noninvasive assessment by ultrasonic tissue characterization.
Fatema K; Hirono O; Takeishi Y; Nitobe J; Kaneko K; Ito M; Masakane I; Kubota I
Heart Vessels; 2002 Sep; 16(6):227-31. PubMed ID: 12382031
[TBL] [Abstract][Full Text] [Related]
15. Impact of azelnidipine treatment on left ventricular diastolic performance in patients with hypertension and mild diastolic dysfunction: multi-center study with echocardiography.
Ito H; Ishii K; Iwakura K; Nakamura F; Nagano T; Takiuchi S
Hypertens Res; 2009 Oct; 32(10):895-900. PubMed ID: 19680260
[TBL] [Abstract][Full Text] [Related]
16. Left atrial remodeling and response to valsartan in the prevention of recurrent atrial fibrillation: the GISSI-AF echocardiographic substudy.
Staszewsky L; Wong M; Masson S; Raimondi E; Gramenzi S; Proietti G; Bicego D; Emanuelli C; Pulitanò G; Taddei F; Nicolis EB; Correale E; Fabbri G; Bertocchi F; Franzosi MG; Maggioni AP; Tognoni G; Disertori M; Latini R;
Circ Cardiovasc Imaging; 2011 Nov; 4(6):721-8. PubMed ID: 21926261
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin receptor blocker improves coronary flow velocity reserve in hypertensive patients: comparison with calcium channel blocker.
Kamezaki F; Tasaki H; Yamashita K; Shibata K; Hirakawa N; Tsutsui M; Kouzuma R; Nagatomo T; Adachi T; Otsuji Y
Hypertens Res; 2007 Aug; 30(8):699-706. PubMed ID: 17917317
[TBL] [Abstract][Full Text] [Related]
18. Potential protective effect of long-term therapy with Xuezhikang on left ventricular diastolic function in patients with essential hypertension.
Ye P; Wu CE; Sheng L; Li H
J Altern Complement Med; 2009 Jul; 15(7):719-25. PubMed ID: 19552598
[TBL] [Abstract][Full Text] [Related]
19. Valsartan, an angiotensin II type-I receptor blocker, and left ventricular diastolic function--a case report.
Okura Y; Nakashima Y; Tojo H; Tashiro E; Saku K
Angiology; 2005; 56(4):467-73. PubMed ID: 16079931
[TBL] [Abstract][Full Text] [Related]
20. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).
Müller-Brunotte R; Kahan T; Malmqvist K; Ring M; Edner M
Am J Hypertens; 2006 Sep; 19(9):927-36. PubMed ID: 16942935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
